The market for anti-obesity drugs has been growing for a while, but is finally about to take off with the entry of two global ...

British industry leaders fear tariffs imposed by President Trump could disrupt the supply and even the price of drugs ...

Eli Lilly's foray into telehealth shows the emerging importance virtual care platforms are playing in the rising popularity ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research ...

The obesity drug market has experienced a seismic shift in recent years, with Novo Nordisk's (NOV: N) Wegovy (semaglutide) ...

In a report released on April 9, Tim Anderson from Bank of America Securities maintained a Buy rating on Eli Lilly and ...

British industry leaders fear tariffs imposed by President Trump could disrupt the supply and even the price of drugs ...

Roche's strong U.S. presence and diversified product portfolio may mitigate the impact of potential tariffs, making it a ...

Once-weekly treatment with tirzepatide can produce clinically meaningful and sustained weight loss for at least 3 years in adults with overweight or ...

As obesity rates rise among individuals with T1D, GLP-1 agonist medications, indicated for T2D and weight loss, are ...